SS Innovations International Inc. (NASDAQ: SSII) announced record first-quarter 2026 financial results, highlighting accelerating commercial adoption of its SSi Mantra surgical robotic platform as the company continues expanding internationally and pursuing regulatory approvals in major healthcare markets. Revenue increased 116.8% year over year to $11.1 million, driven primarily by higher installations of the SSi Mantra system and increased procedure volumes. Gross profit rose to $5.3 million from $1.1 million a year earlier.
The installed base reached 194 SSi Mantra systems across 11 countries, with nearly 9,750 cumulative robotic procedures completed as of the end of the first quarter. As of June 22, 2026, the cumulative number of multi-specialty procedures totaled 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Approximately 2,100 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of procedures.
Regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines expanded the company's international market access during the quarter. SS Innovations recently completed the world's longest-distance robotic cardiac telesurgery in history, demonstrating the capabilities of its remote surgery platform. The company continues pursuing regulatory clearance in both the United States and Europe while expanding its presence in emerging healthcare markets.
For more information, visit the company's website at SSInnovations.com.
